ライフサイエンスコーパス: thiotepa

1 eived combined chemotherapy of docetaxel and thiotepa.

2 administration of the chemotherapeutic drug thiotepa.

3 rapy with cyclophosphamide, carboplatin, and thiotepa.

4 sduced cells were treated with four doses of thioTEPA (10 mg/kg) given over 7 weeks.

5 ification with cyclophosphamide 1,500 mg/m2, thiotepa 125 mg/m2, and carboplatin 200 mg/m2 by IV cont

6 ous infusion of cyclophosphamide 1.5 g/m2/d, thiotepa 125 mg/m2/d, and carboplatin 200 mg/m2/d follow

7 (2) [day 1], carmustine 400 mg/m(2) [day 2], thiotepa 2 x 5 mg/kg [days 3 and 4], and infusion of ste

8 rexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2) on day 4 (group C), with the three g

9 rexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2) on day 4 (group C), with the three g

10 Calvert formula) on days -8, -7, and -6; and thiotepa 300 mg/m2 and etoposide 250 mg/m2 on days -5, -

11 Thiotepa 300 mg/m2 and etoposide 500 mg/ m2 were infused

12 tal dose of 8.4 g/m2 with leucovorin rescue; thiotepa 35 mg/m2; vincristine 1.4 mg/m2; dexamethasone;

13 1), cytarabine 3 g/m(2) (days 2 and 3), and thiotepa 40 mg/m(2) (day 3).

14 ASCT (carmustine 400 mg/m(2) on day -6, and thiotepa 5 mg/kg every 12 h on days -5 and -4, followed

15 ), followed by cyclophosphamide 6,000 mg/m2, thiotepa 500 mg/m2, and carboplatin 800 mg/m2 (CTCb) wit

16 ion cycle of cyclophosphamide (6,000 mg/m2), thiotepa (500 mg/ m2), and carboplatin (800 mg/m2) (CTCb

17 00 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (CBT regimen).

18 actionated 15 Gy)/melphalan (180 mg/m(2)) or thiotepa (900 mg/m(2))/carboplatin (1,500 mg/m(2)).

19 radiotherapy and a myeloablative regimen of thiotepa (900 mg/m2) plus carboplatin (1,500 mg/m2), wit

20 ic agents (ie, methotrexate, cytarabine, and thiotepa) administered by a variety of schedules either

21 ble of penetrating the blood-brain barrier - thioTEPA and 5-fluorouracil - influence the normal proce

22 -dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transpla

23 HCT-ASCT with thiotepa and carmustine is an effective treatment option

24 atin, thiotepa, and etoposide (16 patients), thiotepa and etoposide (three patients), or thiotepa, et

25 ery proceeded to high-dose chemotherapy with thiotepa and etoposide and autologous peripheral blood s

26 The combination of high-dose thiotepa and etoposide has activity against a variety of

27 sulfan (busulfan in 1 patient), fludarabine, thiotepa, and anti-thymocyte globulin or alemtuzumab con

28 lternative to single-cycle cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification, we eva

29 hamide (original protocol) or with busulfan, thiotepa, and cyclophosphamide (modified protocol).

30 single course of high doses of carboplatin, thiotepa, and cyclophosphamide plus transplantation of a

31 of hyperfractionated total body irradiation, thiotepa, and cyclophosphamide.

32 ng with fractionated total-body irradiation, thiotepa, and cyclophosphamide.

33 rapy was then administered with carboplatin, thiotepa, and etoposide (16 patients), thiotepa and etop

34 chemotherapy that incorporated carboplatin, thiotepa, and etoposide followed by ABMR.

35 evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue

36 ng conditioning with total body irradiation, thiotepa, and fludarabine.

37 fractionated total body irradiation (HFTBI), thiotepa, and fludarabine.

38 demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is t

39 matopoietic cells were resistant in vitro to thioTEPA at multiple concentrations.

40 herapy and/or radiotherapy were treated with thiotepa-based HDC regimens followed by ASCR.

41 hamide (BU/CY), busulfan plus melphalan plus thioTEPA (BUMELTT), or melphalan before transplant.

42 ts with advanced leukemia received high-dose thiotepa, busulfan, and cyclophosphamide as a preparativ

43 The preparative regimen consisted of thiotepa, busulfan, and cyclophosphamide.

44 novel consolidation high-dose chemotherapy (thiotepa, busulfan, cyclophosphamide) and autologous ste

45 h methotrexate-cytarabine plus rituximab and thiotepa, but infective complications were similar in th

46 The three patients treated with thiotepa/carboplatin relapsed 3 to 4 months after transp

47 Four patients received thiotepa/carboplatin: two were in CR and remain so, and

48 mbination with cisplatin (CI=0.48, P=0.003), thiotepa (CI=0.67, P=0.0008), and etoposide (CI=0.54, P=

49 st induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m(2) on day

50 luded older age (P <.01), busulfan/melphalan/thiotepa conditioning (P <.01), interleukin-2 (P =.02),

51 es of adjuvant chemotherapy with intrathecal thiotepa, consolidation chemotherapy, and autologous ste

52 overall results are encouraging, mostly when thiotepa-containing conditioning regimens are used, both

53 sponse proceeded with consolidation HDC with thiotepa, cyclophosphamide, and busulfan, followed by AS

54 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarab

55 sponse rate, and outcome following high-dose thiotepa, etoposide, and autologous bone marrow rescue (

56 thiotepa and etoposide (three patients), or thiotepa, etoposide, and carmustine (BCNU; one patient).

57 = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1).

58 22-38), patients treated with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38

59 ro, nor on the antitumor activity of 5-FU or thiotepa in BALB/c mice implanted with P388 leukemia cel

60 ncrease resistance of hematopoietic cells to thioTEPA-induced cytotoxicity.

61 G1 protein protects hematopoietic cells from thioTEPA-induced DNA damage and suggest that a high leve

62 may provide an novel approach to preventing thioTEPA-induced toxicity of primary hematopoietic cells

63 N,N',N"-Triethylenethiophosphoramide (thioTEPA) induces the formation of amino-ethyl adducts o

64 tion with clinical efficacy of docetaxel and thiotepa on metastatic breast cancer patients; and metas

65 randomization to high-dose cyclophosphamide/thiotepa or observation (Intergroup Trial 0121).

66 efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy

67 ukocytes, hemoglobin, and platelet counts of thioTEPA-treated Fpg mice were significantly higher than

68 lineage regeneration after high-dose 5-FU or thiotepa treatment in BALB/c mice.

69 ntation (HSCT) after a preparation combining thiotepa, treosulfan, and fludarabine.

70 The ablative regimens included: (1) thiotepa (TT)/cyclophosphamide (CTX)/carboplatin (CP; n

71 ly, asymptomatic patients were enrolled in a thiotepa up-front therapeutic window.

72 Response rate to thiotepa was 78%.

73 thioTEPA was found to yield a pronounced dose-related in